Advertisement
ENTX vs JSPR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTX is a StrongBuy and JSPR is a Hold.
ENTX's RSI Indicator climbs out of oversold territory
The RSI Indicator for ENTX moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 33 of the 35 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on ENTX as a result. In 76 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for ENTX just turned positive on October 16, 2026. Looking at past instances where ENTX's MACD turned positive, the stock continued to rise in 47 of 53 cases over the following month. The odds of a continued upward trend are 89%.
ENTX moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTX advanced for three days, in 180 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ENTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for ENTX crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ENTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ENTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ENTX's P/B Ratio (71.964) is slightly higher than the industry average of (2.973). P/E Ratio (-8.629) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1428.571) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
JSPR sees its Stochastic Oscillator ascending out of oversold territory
On October 22, 2026, the Stochastic Oscillator for JSPR moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 64 instances where the indicator left the oversold zone. In 55 of the 64 cases the stock moved higher in the following days. This puts the odds of a move higher at over 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JSPR's RSI Indicator exited the oversold zone, 38 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
Following a +5.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where JSPR advanced for three days, in 201 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
JSPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JSPR as a result. In 84 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for JSPR turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 34 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for JSPR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.671) is normal, around the industry mean (2.973). P/E Ratio (-0.533) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. JSPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ENTX | JSPR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 88 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 35 | 86 | |
P/E GROWTH RATING 1..100 | 90 | 14 | |
SEASONALITY SCORE 1..100 | n/a | 16 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JSPR's Valuation (81) in the null industry is in the same range as ENTX (95) in the Pharmaceuticals Major industry. This means that JSPR’s stock grew similarly to ENTX’s over the last 12 months.
JSPR's Profit vs Risk Rating (100) in the null industry is in the same range as ENTX (100) in the Pharmaceuticals Major industry. This means that JSPR’s stock grew similarly to ENTX’s over the last 12 months.
ENTX's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as JSPR (100) in the null industry. This means that ENTX’s stock grew similarly to JSPR’s over the last 12 months.
ENTX's Price Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for JSPR (86) in the null industry. This means that ENTX’s stock grew somewhat faster than JSPR’s over the last 12 months.
JSPR's P/E Growth Rating (14) in the null industry is significantly better than the same rating for ENTX (90) in the Pharmaceuticals Major industry. This means that JSPR’s stock grew significantly faster than ENTX’s over the last 12 months.
| ENTX | JSPR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 4 days ago 84% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 89% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 90% |
| Advances ODDS (%) | 2 days ago 78% | 2 days ago 83% |
| Declines ODDS (%) | 10 days ago 89% | 4 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ENTX’s FA Score shows that 0 FA rating(s) are green while JSPR’s FA Score has 1 green FA rating(s).
- ENTX’s FA Score: 0 green, 5 red.
- JSPR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ENTX’s TA Score shows that 6 TA indicator(s) are bullish while JSPR’s TA Score has 4 bullish TA indicator(s).
- ENTX’s TA Score: 6 bullish, 4 bearish.
- JSPR’s TA Score: 4 bullish, 4 bearish.
Price Growth
ENTX (@Biotechnology) experienced а +22.00% price change this week, while JSPR (@Biotechnology) price change was +0.66% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
ENTX is expected to report earnings on Nov 13, 2026.
JSPR is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ENTX and
Correlation & Price change
A.I.dvisor tells us that ENTX and JSPR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENTX and JSPR's prices will move in lockstep.
| Ticker / NAME | Correlation To ENTX | 1D Price Change % | ||
|---|---|---|---|---|
| ENTX | 100% | -0.98% | ||
| JSPR - ENTX | 32% Poorly correlated | -1.73% | ||
| MLTX - ENTX | 30% Poorly correlated | +15.87% | ||
| QCLS - ENTX | 26% Poorly correlated | +3.50% | ||
| NTLA - ENTX | 26% Poorly correlated | -4.21% | ||
| LGVN - ENTX | 25% Poorly correlated | +11.19% | ||
More | ||||
JSPR and
Correlation & Price change
A.I.dvisor indicates that over the last year, JSPR has been loosely correlated with AUPH. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if JSPR jumps, then AUPH could also see price increases.
| Ticker / NAME | Correlation To JSPR | 1D Price Change % | ||
|---|---|---|---|---|
| JSPR | 100% | -1.73% | ||
| AUPH - JSPR | 44% Loosely correlated | +2.54% | ||
| IMRX - JSPR | 39% Loosely correlated | +1.87% | ||
| FRMM - JSPR | 38% Loosely correlated | -6.20% | ||
| NXTC - JSPR | 37% Loosely correlated | -12.83% | ||
| OCS - JSPR | 33% Poorly correlated | +2.80% | ||
More | ||||